Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CAMP vs SLS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SLS Captures Overall Composite Edge (34.1 SELL vs 43.9 HOLD), While CAMP Leads 3–2 on Growth & Valuation Pillars
SLS Overall Winner
6-Pillar Tally: CAMP 3 – 2 SLS (1 Tie)
Matrix Metrics: CAMP 3 – 4 SLS
As of Nov 17, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (34.1/100 SELL vs. 43.9/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus SLS at $19.68 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. SLS 34.1/100 SELL), SLS captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -991.8% operating margin) and revenue trajectory (-82.5% vs. +138.9% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CAMP vs SLS
CAMP
CAMP4 Therapeutics Corporation Common Stock
$3.95
+2.33% 1D
Market Cap
$238.5M
TTM Revenue
$5.3M
Forward P/E
N/M
Beta / 30D Vol
1.34β · 94% Vol
Unified Composite Score
43.9
HOLD
Tech 34.0
Fund 40.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
SLS
Head-to-Head Winner
SELLAS Life Sciences Group, Inc. Common Stock
$19.68
+163.41% 1D
Market Cap
$1.6B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.72β · 567% Vol
Unified Composite Score
34.1
SELL
Tech 5.0
Fund 37.0
Flow 66.0
Mom 38.9
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CAMP 3 – 2 SLS)
1. Valuation Multiples
CAMP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
26.6x
N/M
2. Growth & Scale
CAMP
Revenue Growth (YoY)
+138.9%
-82.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$5.3M
N/A
Market Cap
$238.5M
$1.6B
3. Profitability & Quality
SLS
Gross Margin
N/A
N/A
Operating Margin
-991.8%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-146.1%
-40.3%
4. Balance Sheet & Cash Flow
CAMP
Cash Generation (TTM)
-$26M
-$28M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$97M Net Cash
$138M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SLS
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
N/A (N/A)
545.8% (74th %ile)
Put/Call OI Skew
N/A
0.39x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CAMP (3) vs SLS (4)| Institutional Metric | CAMP | SLS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $238.5M | $1.6B | SLS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +138.9% | -82.5% | CAMP | |
| Operating Margin (TTM) | -991.8% | 0.0% | SLS | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -146.1% | -40.3% | SLS | |
| 52-Week Range Position | 22% ($3–$8) | 78% ($1–$25) | SLS | |
| Beta / 30D Volatility | 1.34β · 94% Vol | 1.72β · 567% Vol | CAMP | |
| Unified Institutional Score | 43.9 / 100 (HOLD) | 34.1 / 100 (SELL) | CAMP | |
| Trailing 12M Revenue (USD) | $5.3M | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 26.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$26M ($97M Net Cash) | -$28M ($138M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SLS +61.78 pp
3M Horizon
SLS +57.12 pp
6M Horizon
SLS +164.07 pp
1Y Horizon
SLS +1279.66 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CAMP Revenue | SLS Revenue | CAMP Op. Margin | SLS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2013 | N/A | $0M | N/A | -1145.5% | SLS |
| FY2014 | N/A | $10M | N/A | -471.1% | SLS |
| FY2020 | N/A | $0M | N/A | -893.8% | SLS |
| FY2021 | N/A | $10M | N/A | -332.8% | SLS |
| FY2022 | N/A | $0M | N/A | -4195.0% | SLS |
| FY2023 | $0M | N/A | -14822.6% | N/A | CAMP |
| FY2024 | $0M | N/A | -8142.3% | N/A | CAMP |
| FY2025 | $0M | N/A | -1502.4% | N/A | CAMP |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CAMP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SLS
BREAKOUT
Current IV
545.8%
IV Percentile
74th %ile
Put/Call OI Skew
0.39x (Call-Skewed)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact SLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CAMP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SLS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CAMP vs SLS Key Questions & Quantitative Answers
As of Nov 17, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (34.1/100 SELL vs. 43.9/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus SLS at $19.68 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. SLS 34.1/100 SELL), SLS captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -991.8% operating margin) and revenue trajectory (-82.5% vs. +138.9% YoY).
CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with SLS at -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), CAMP cumulative revenue shifted N/A while SLS shifted +0.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLS.
CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus SLS (-40.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, SLS carries 545.8% implied volatility (74th %ile, Elevated (60th–80th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.72β · 567% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SLS vs CAMP · Reverse Pair
CAMP vs HLIT
· Sector Peer
CAMP vs ADTN
· Sector Peer
CAMP vs DGII
· Sector Peer
SLS vs GLSI
· Sector Peer
SLS vs IMMP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem